<?xml version="1.0" encoding="UTF-8"?>
<p>According to the drugâ€“drug interactions study conducted by Liverpool University for anti-SARS-CoV-2 drugs, tocilizumab should not be administered with the following agents: metamizole (high risk of hematological toxicity), immunosuppressants (adalimumab and basiliximab), and lipid lowering agents (evolocumab) [
 <xref rid="B80-jcm-09-02084" ref-type="bibr">80</xref>]. Coadministration with other investigated agents for COVID-19 therapy such as chloroquine, hydroxychloroquine (potential additive toxicity), and ribavirin (risk of hematological toxicity) requires close monitoring and possible dose adjustment. No interactions were reported between tocilizumab and lopinavir/ritonavir or remdesivir [
 <xref rid="B80-jcm-09-02084" ref-type="bibr">80</xref>].
</p>
